Why the study?
Disparities between women and men persist in the diagnosis, treatment, and prognosis of ASCVD, highlighting the need to feature existing data on differential guidelines, care implementation, and outcomes.
Answers are grounded in this paper and cite their sources.
This review emphasizes the persistent sex-based disparities in ASCVD management and outcomes, underscoring the need for improved representation of women in clinical trials and tailored approaches to care.
Disparities between women and men persist in the diagnosis, treatment, and prognosis of atherosclerotic cardiovascular disease (ASCVD). Despite growing attention to sex-based differences in cardiovascular care, there are continued disparities in short- and long-term outcomes. Such disparities highlight the need to identify pathophysiologic differences in treatment patterns for stable ischemic heart disease, non-ST elevation myocardial infarction (NSTE-ACS), ST-elevation myocardial infarction (STEMI), and myocardial infarction with non-obstructive coronary arteries (MINOCA). The role of age as an effect modifier should also be considered given that young women diagnosed with ACS continue to experience increased rates of in-hospital mortality and major adverse cardiovascular events. Both patient-directed and systems-based approaches remain integral to improve outcomes in cardiovascular care. While inadequate representation of women in clinical trials remains a barrier to the implementation of evidence-based therapies, a growing body of data has established the efficacy and safety of medications in women across acute coronary syndromes. This review seeks to feature existing data on the differential treatment guidelines, care implementation, and cardiovascular outcomes between women and men, highlighting next directions for clinical investigation.
No takes yet. Share an insight, caveat, or question.
Holtzman et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: